Time to hit HIV, early and hard.

Early treatment of asymptomatic human immunodeficiency virus type 1 (HIV-1) infection remains controversial. In the AIDS Clinical Trials Group 019 study, zidovudine was shown in 1990 to slow the cl...

[1]  A. Perelson,et al.  Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection , 1995, Nature.

[2]  S. Vasavanonda,et al.  ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[3]  D. Ho,et al.  Quantitation of human immunodeficiency virus type 1 in the blood of infected persons. , 1989, The New England journal of medicine.

[4]  S. J. Clark,et al.  High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR. , 1993, Science.

[5]  Ann Marie Swart,et al.  Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection , 1994, The Lancet.

[6]  S. J. Clark,et al.  High titers of cytopathic virus in plasma of patients with symptomatic primary HIV-1 infection. , 1991, The New England journal of medicine.

[7]  S W Lagakos,et al.  Zidovudine in Asymptomatic Human Immunodeficiency Virus Infection , 1990 .

[8]  D. Ho,et al.  Transient high levels of viremia in patients with primary human immunodeficiency virus type 1 infection. , 1991, The New England journal of medicine.

[9]  J. Phair,et al.  A comparison of immediate with deferred zidovudine therapy for asymptomatic HIV-infected adults with CD4 cell counts of 500 or more per cubic millimeter. AIDS Clinical Trials Group. , 1995, The New England journal of medicine.

[10]  Martin A. Nowak,et al.  Viral dynamics in human immunodeficiency virus type 1 infection , 1995, Nature.

[11]  D. Ho,et al.  Clinical evaluation of branched DNA signal amplification for quantifying HIV type 1 in human plasma. , 1995, AIDS research and human retroviruses.

[12]  D. Ho,et al.  Genotypic and phenotypic characterization of HIV-1 patients with primary infection. , 1993, Science.

[13]  B. Korber,et al.  Selective transmission of human immunodeficiency virus type-1 variants from mothers to infants. , 1992, Science.

[14]  E. Holmes,et al.  Selection for specific sequences in the external envelope protein of human immunodeficiency virus type 1 upon primary infection , 1993, Journal of virology.

[15]  J. Coffin,et al.  HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy , 1995, Science.

[16]  D. Hawkins,et al.  A controlled trial of zidovudine in primary human immunodeficiency virus infection. , 1995, The New England journal of medicine.

[17]  P. Darke,et al.  L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[18]  J. Mellors,et al.  Quantitation of HIV-1 RNA in Plasma Predicts Outcome after Seroconversion , 1995, Annals of Internal Medicine.

[19]  L. Loeb,et al.  Fidelity of HIV-1 reverse transcriptase. , 1988, Science.